Company intelligence / Profile preview

SQY Therapeutics

Guyancourt, Île-de-France / Yvelines, Francesqy-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SQY Therapeutics has developed a next-generation tricyclo-DNA antisense oligonucleotide platform. Its lead candidate targets exon 51 skipping in the dystrophin gene to treat Duchenne Muscular Dystrophy and is advancing toward or entering Phase 1/2a trials. The company’s tcDNA ASOs show improved RNA binding affinity and tissue distribution compared to earlier generations, with potential applications across multiple genetic diseases. No published clinical results are available yet.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Antisense oligonucleotideTricyclo-DNA class (tcDNA) antisense oligonucleotide
Industry: Biotech

Drug pipeline

4 assets

SQY51

3 more assets in the full pipeline.

Partnerships

Association Monégasque contre les Myopathies (AMM)Duchenne Parent Project France

Beyond the preview

Go deeper on SQY Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQY Therapeutics.